| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-07-22 | Cevec Pharmaceuticals (Germany) | € 4.5 million | financing round | Investtodate GmbH (Germany) Frank Ubags, CEO, and Nicole Faust, CSO of CEVEC (Germany) Peppermint VenturePartners GmbH (Germany) Creathor Venture Management GmbH (Germany) NRW.Bank (Germany) KfW Bank (Germany) G.A.T. Holding (Germany) private individuals. | Technology - Services | Financing round |
| 2015-07-21 | Ultragenyx Pharmaceutical (USA - CA) | $286.6 million | private placement | Rare diseases - Genetic diseases - Metabolic diseases | Private placement | |
| 2015-07-20 | Sensorion (France) | €8 million | capital increase | undisclosed international family office specialised in life sciences | Otorhinolaryngology | Capital increase |
| 2015-07-20 | DBV Technologies (France) | $281.5 million | private placement | Allergic diseases | Private placement | |
| 2015-07-16 | Immunocore (UK) | $320 million (£205 million) | series A financing round | Woodford Investment Management (UK) Malin Corporation (UK) Eli Lilly (USA - IN) RTW Investments (USA - NY) new and existing investors | Autoimmune diseases - Cancer - Oncology - Infectious diseases | Series A financing round |
| 2015-07-15 | Innavirvax (France) | €3.6 Million | series C financing round | FCPR CapDecisif 2 (France) G1J Ile-de-France (France) Pradeyrol Development (France) Fa Dièse (France) FRCI (Fonds Régional de Co-Investissement d’Ile-de-France) (France) | Infectious diseases | Series C financing round |
| 2015-07-10 | Clovis Oncology (USA - CO) | $275 million | private placement | Cancer - Oncology | Private placement | |
| 2015-07-08 | Eligo Bioscience (France) | € 2 million | financing round | Seventure (France) | Infectious diseases | Financing round |
| 2015-07-08 | Biophytis (France) | € 10 million | IPO | IPO | ||
| 2015-07-07 | 4SC (Germany) | € 29 million | capital increase | Santo Holding (Germany) Wellington Partners (UK) existing investors | Cancer - Oncology | Capital increase |
| 2015-07-06 | Cassiopea (Switzerland) | CHF 175.6 million (€169.1 million) | IPO | Dermatological diseases | IPO | |
| 2015-07-02 | Horama (France) | € 150,000 | grant | French ministry for higher education and research (France) | Ophtalmological diseases | Grant |
| 2015-07-02 | Neovacs (France) | € 7.5 million | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Capital increase | ||
| 2015-07-01 | Seres Therapeutics (USA - MA) | $139.8 million | IPO | Metabolic diseases - Digestive diseases - Infectious diseases | IPO | |
| 2015-07-01 | Corvus Pharmaceuticals (USA - CA) | $33.5 million (€ 30.08 milion) | series A financing round | OrbiMed (USA - NY) Adams Street Partners (USA) Novo Ventures (Denmark) | Cancer - Oncology | Series A financing round |
| 2015-06-29 | Sarepta Therapeutics (USA - MA) | $40 million | loan | Midcap Financial (USA - MD) | Rare diseases - Genetic diseases - Neuromuscular diseases | Loan |
| 2015-06-26 | Vaxxilon (Switzerland) | up to €30 million | financing round | Actelion (Switzerland) | Infectious diseases | Financing round |
| 2015-06-24 | MDX Health (Belgium) | € 27.7 million | private placement | Cancer - Oncology - Diagnostic | Private placement | |
| 2015-06-24 | ViraTherapeutics (Austria) | €3.6 million | series A financing round | Boehringer Ingelheim Venture Fund (BIVF) (Germany) EMBL Ventures (Germany) Austria Wirtschaftsservice (Austria) | Cancer - Oncology | Series A financing round |
| 2015-06-24 | Celyad (Belgium) | €88.0 million ($100.1 million) | IPO | Cardiovascular diseases - Regenerative diseases | IPO |
